
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
AVEO Oncology | Tivozanib | Highly refractory advanced or metastatic renal cell carcinoma (RCC) | Met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS) in Phase III clinical trial |
Fortis Therapeutics, Inc. | FOR46 | Metastatic castration-resistant prostate cancer and late-stage multiple myeloma | The FDA has cleared two Investigational New Drug (IND) applications |
Shoulder Innovations | InSet Humeral Short Stem System | Degenerative, rheumatoid or traumatic arthritis in the shoulder | Received 510(k) clearance from the FDA |
Eli Lilly | Trulicity (dulaglutide) | Heart attacks and stroke in type 2 diabetes | Reduced major adverse cardiovascular events (MACE) in REWIND Phase III clinical trial |
Themis Bioscience | MV-CHIK | Chikungunya fever | Primary endpoint —neutralizing antibodies after one or two injections — was met in Phase II clinical trial |
Bristol-Myers Squibb | Empliciti (elotuzumab) | Multiple myeloma in adults who have received at least two prior therapies |
Granted approval by the FDA |
Bone Therapeutics | PREOB | Hip osteonecrosis (ON) | Halted Phase III trial after interim analysis showed it would not meet endpoints |
Endo International plc | Collagenase clostridium histolyticum (CCH) | Cellulite | Positive results announced from two identical Phase III RELEASE* clinical trials |
Mallinckrodt plc | H.P. Acthar Gel | Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) | First patient screened in company's Phase IV, multi-center, multiple-dose, open label trial to assess effect |
OncoSec Medical | TAVO™ (in combination with Merck's KEYTRUDA®) | Late-stage triple negative breast cancer (TNBC) | First patient treated in KEYNOTE-890 Phase II clinical trial |
Glenmark Pharmaceuticals | CD38xCD3 bispecific antibody GBR 1342 | Solid tumors | Launching a Phase I clinical trial |
BD | LUTONIX® 014 Drug-Coated Balloon (DCB) IDE |
Narrowed or obstructed arteries below the knee |
Primary safety and efficacy endpoints were met in Phase I clinical trial |
Urovant Sciences, Inc. | Vibegron | Overactive bladder | Completed enrollment in international Phase III clinical trial, EMPOWUR to evaluating safety and efficacy |
Upcoming Events
-
14Apr